Kezar Life SciencesKZR
13F holders, Q3 2024 (September 30)3holders +2
2new positions
0sold out
$0.77avg. 13F price*
At the end of Q3 2024, 3 institutions reported holding Kezar Life Sciences Inc. (KZR) in their 13F filings, up 2 from Q2 2024. 2 opened new positions and 0 sold out. The largest holders were ADAR1 Capital Management, LLC ($1.0M), T. Rowe Price Associates Inc. ($65K) and Catalyst Funds Management Pty Ltd ($14K).
- Company
- Kezar Life Sciences Inc.
- CUSIP
- 49372L209
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $1.1M |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 1,421,873 shares bought, net +1,421,873 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| ADAR1 Capital Management, LLC | 0.17% | New | 1,338,273 | $1.0M |
| T. Rowe Price Associates Inc. | 0.00% | New | 83,600 | $65K |
| Catalyst Funds Management Pty Ltd | 0.00% | No change | 18,300 | $14K |
"% of holder's portfolio" is KZR's weight in each manager's 13F, not the share of Kezar Life Sciences Inc. the manager owns.